Sanofi SA
PAR:SAN

Watchlist Manager
Sanofi SA Logo
Sanofi SA
PAR:SAN
Watchlist
Price: 85 EUR 0.51% Market Closed
Market Cap: 104.3B EUR

During the last 3 months Sanofi SA insiders have not bought any shares, and have not sold any shares. The stock price has increased by 7% over this period (open performance analysis).

The last transaction was made on Jul 26, 2022 by Wolfgang Laux , who bought 20.1k EUR worth of SAN shares.

Last Transactions:
Wolfgang Laux
€+20.1k
Wolfgang Laux
€+1k
Wolfgang Laux
€-4.9k
Christophe Babule
€+36.5k
Emmanuel Babeau
€+37.6k
Sanofi
€+32.9k
Bernard Charlès
€+32.3k
Karen Linehan
€+1.5m
Karen Linehan
€-2.6m
Elias Zerhouni
€-527k
Jerome Contamine
€+846.6k
Jerome Contamine
€-1.2m
Peter Guenter
€-851.2k
Peter Guenter
€+498.2k
Thomas Südhof
€+40.5k
View All Transactions

During the last 3 months Sanofi SA insiders have not bought any shares, and have not sold any shares. The stock price has increased by 7% over this period (open performance analysis).

The last transaction was made on Jul 26, 2022 by Wolfgang Laux , who bought 20.1k EUR worth of SAN shares.

Sold
0-3
months
0 EUR
0
3-6
months
0 EUR
0
6-9
months
0 EUR
0
9-12
months
0 EUR
0
Bought
0-3
months
No Insider Transactions
0
0 EUR
3-6
months
No Insider Transactions
0
0 EUR
6-9
months
No Insider Transactions
0
0 EUR
9-12
months
No Insider Transactions
0
0 EUR

Sanofi SA
Insider Trading Chart

Sanofi SA
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Sanofi SA
Last Insider Transactions

Global
Insiders Monitor

Sanofi SA
Glance View

Sanofi SA, a titan in the global healthcare sector, operates at the intricate crossroads of pharmaceutical innovation and patient care, driven by an unyielding commitment to improving human health. Emerging from its French roots, Sanofi has strategically positioned itself as a global leader in pharmaceuticals, vaccines, and consumer healthcare. The company’s success is essentially anchored in its capacity to consistently develop and commercialize life-saving drugs that address a myriad of health concerns, ranging from diabetes and cardiovascular diseases to rare disorders and oncology. Underlining its robust revenue engine is Sanofi's extensive R&D infrastructure that fuels its pipeline with groundbreaking therapies, reflecting a dynamic blend of scientific acumen and market-focused agility. By leveraging a hybrid model that integrates cutting-edge research with strategic alliances and acquisitions, Sanofi ensures a sustained presence in the highly competitive biopharmaceutical landscape. Enabling this network of innovation and impact is Sanofi's diverse portfolio, a balanced mix of specialty and established prescription drugs, over-the-counter products, and the critical arm of vaccines led by its Sanofi Pasteur division. This diversification offers both growth opportunities and stability, cushioning against the volatile tides of patent expirations and regulatory changes. Its vaccines segment, in particular, is a cornerstone in Sanofi's business, capturing substantial market share with products critical to global immunization efforts, further amplified by its role in responding to health emergencies like the COVID-19 pandemic. With a geographically expansive sales footprint and strategic marketing strategies, Sanofi capitalizes on emerging market opportunities while maintaining a strong presence in established regions, effectively making its bottom line a testimony to its operational excellence and strategic foresight in harmonizing science with humanity.

SAN Intrinsic Value
154.73 EUR
Undervaluation 45%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top